Valuation : Structure Therapeutics Inc.

Market Cap 3.38B 2.9B 2.73B 2.49B 4.66B 319B 4.68B 32.38B 12.51B 163B 12.68B 12.4B 521B P/E 2026 *
-29.2x
P/E 2027 * -21.6x
Enterprise Value 2.41B 2.07B 1.95B 1.78B 3.33B 228B 3.34B 23.1B 8.93B 117B 9.05B 8.85B 372B EV / Sales 2026 *
62.6x
EV / Sales 2027 * 67,593x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+3.11%
Current month+3.11%
1 month-10.91%
3 months+25.97%
6 months-18.00%
Current year-31.93%
1 week 46.07
Extreme 46.07
48.64
1 month 45.1
Extreme 45.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 20.04
Extreme 20.04
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
4/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.11%+114.40%+65.70% 3.38B
-0.38%-0.99%+42.69%+100.85% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-0.50%-2.51%+23.76%+12.97% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-5.02%+219.82%+379.02% 17.16B
-1.10%-1.39%-8.26%+518.44% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.47%+0.88%+48.56%+166.95% 28.25B
Weighted average by Cap. -0.81%+0.46%+37.46%+138.12%

Financials

2026 *2027 *
Net sales 38.46M 33.08M 31.11M 28.4M 53.11M 3.64B 53.28M 369M 143M 1.86B 144M 141M 5.93B 41.67K 35.84K 33.71K 30.77K 57.54K 3.94M 57.73K 400K 154K 2.02M 156K 153K 6.43M
Net income -309M -265M -250M -228M -426M -29.18B -427M -2.96B -1.14B -14.94B -1.16B -1.13B -47.59B -475M -409M -385M -351M -656M -44.96B -659M -4.56B -1.76B -23.02B -1.79B -1.75B -73.33B
Net Debt -967M -832M -782M -714M -1.34B -91.47B -1.34B -9.28B -3.59B -46.84B -3.63B -3.55B -149B -559M -481M -452M -413M -772M -52.89B -775M -5.36B -2.07B -27.08B -2.1B -2.05B -86.27B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
04/09/26 USD 47.34 0.00% 281,709
03/09/26 USD 47.34 -0.96% 621,486
02/09/26 USD 47.80 +1.42% 1,064,737
01/09/26 USD 47.13 +2.66% 816,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.34USD
Average target price
104.77USD
Spread / Average Target
+121.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!